165 related articles for article (PubMed ID: 29511780)
1. Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males.
Sangle GV; Patil M; Deshmukh NJ; Shengule SA; Kamble S; Vuppalavanchu KK; Kale S; Baig MLA; Singh G; Shaikh J; Tripathi J; Aravindababu P
Eur J Clin Pharmacol; 2018 May; 74(5):561-569. PubMed ID: 29511780
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
3. Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?
Andersen ES; Lund A; Bagger JI; Andreasen C; Grøndahl MF; Deacon CF; Hartmann B; Holst JJ; Knop FK; Vilsbøll T
Diabetes Obes Metab; 2018 Aug; 20(8):1937-1943. PubMed ID: 29654643
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling of cetagliptin in patients with type 2 diabetes mellitus.
Zhou C; Zhou S; Wang J; Xie L; Lv Z; Zhao Y; Wang L; Luo H; Xie D; Shao F
Front Endocrinol (Lausanne); 2024; 15():1359407. PubMed ID: 38529396
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
Kim TE; Lim KS; Park MK; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 Sep; 34(9):1986-98. PubMed ID: 22943970
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.
Herman GA; Mistry GC; Yi B; Bergman AJ; Wang AQ; Zeng W; Chen L; Snyder K; Ruckle JL; Larson PJ; Davies MJ; Langdon RB; Gottesdiener KM; Wagner JA
Br J Clin Pharmacol; 2011 Mar; 71(3):429-36. PubMed ID: 21284702
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
8. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects.
Dai H; Gustavson SM; Preston GM; Eskra JD; Calle R; Hirshberg B
Diabetes Obes Metab; 2008 Jun; 10(6):506-13. PubMed ID: 18284437
[TBL] [Abstract][Full Text] [Related]
9. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
Murai K; Katsuno T; Miyagawa J; Matsuo T; Ochi F; Tokuda M; Kusunoki Y; Miuchi M; Namba M
Drugs R D; 2014 Dec; 14(4):301-8. PubMed ID: 25420579
[TBL] [Abstract][Full Text] [Related]
10. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
11. A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes.
Fraser IP; Neufeld ND; Fox LA; Kipnes MS; Miller TL; Zeitler PS; Rodriguez H; Gilmartin JH; Lee SJ; Patterson JK; Li XS; Maganti L; Luo WL; Tatosian DA; Stoch SA
Pediatr Diabetes; 2019 Feb; 20(1):48-56. PubMed ID: 30346099
[TBL] [Abstract][Full Text] [Related]
12. Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model.
Davis JA; Kumar PS; Singh S; Surender A; Roy S; Khanna V; Sethi S; Pal C; Sharma L; Benjamin B; Mittra S; Sattigeri J; Bansal VS
Indian J Pharmacol; 2012; 44(6):759-64. PubMed ID: 23248408
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, randomized, placebo and positive-controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptin.
Lu J; Wang L; Zhou S; Zhou C; Xie L; Chen J; Tang D; Tian X; Xie D; Ding J; Wang T; Yu Q; Ding J; Shao F
Br J Clin Pharmacol; 2022 Jun; 88(6):2946-2958. PubMed ID: 34965609
[TBL] [Abstract][Full Text] [Related]
14. Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods.
Liu D; Ma X; Liu Y; Zhou H; Shi C; Wu F; Jiang J; Hu P
Eur J Pharm Sci; 2016 Jun; 89():73-82. PubMed ID: 27108678
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Addy C; Tatosian D; Glasgow XS; Gendrano IN; Kauh E; Martucci A; Johnson-Levonas AO; Selverian D; Matthews CZ; Gutierrez M; Wagner JA; Aubrey Stoch S
Clin Ther; 2016 Mar; 38(3):516-30. PubMed ID: 26869191
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers.
K P A; Meda VS; Kucherlapati VS; Dubala A; M D; P R AV; K E; B S
Eur J Clin Pharmacol; 2012 May; 68(5):709-14. PubMed ID: 22173280
[TBL] [Abstract][Full Text] [Related]
17. Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study.
Schopman JE; Hoekstra JBL; Frier BM; Ackermans MT; de Sonnaville JJJ; Stades AM; Zwertbroek R; Hartmann B; Holst JJ; Knop FK; Holleman F
Diabetes Obes Metab; 2015 Jun; 17(6):546-553. PubMed ID: 25694217
[TBL] [Abstract][Full Text] [Related]
18. Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in β-Cell Function in Patients With Type 2 Diabetes.
Stensen S; Gasbjerg LS; Rosenkilde MM; Vilsbøll T; Holst JJ; Hartmann B; Christensen MB; Knop FK
Diabetes; 2022 Oct; 71(10):2209-2221. PubMed ID: 35796651
[TBL] [Abstract][Full Text] [Related]
19. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
[TBL] [Abstract][Full Text] [Related]
20. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]